Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial
Author:
Affiliation:
1. Department of Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, 200080, China
2. Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China
Publisher
Impact Journals, LLC
Subject
Oncology
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Accurate resection of hilar cholangiocarcinoma using eOrganmap 3D reconstruction and full quantization technique;World Journal of Gastrointestinal Surgery;2023-08-27
2. Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects;Frontiers in Oncology;2023-03-15
3. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden that Responded Significantly to Pembrolizumab but Perforated within a Short Period: A Case Report;Internal Medicine;2023
4. Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect;Hepatobiliary Surgery and Nutrition;2022-12
5. Comparison of Different First-Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta-Analysis;BioMed Research International;2022-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3